Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

United Laboratories Inc.

www.unilab.com.ph

Latest From United Laboratories Inc.

China Regulatory Changes Benefit Lee/RegeneRx Ophthalmic Alliance

China’s allowance of early clinical trials for drugs sourced outside of the country will help domestic companies develop innovative drugs for the domestic market, as shown by the licensing deal between Lee’s Pharma and RegeneRx for a dry eye syndrome treatment. With the China xerophthalmia segment showing rapid growth, the country may eventually become one of the biggest markets in the world for RGN-259.

BioPharmaceutical Asia Pacific

Hunan Tender Creates Industry Jitters In China

The price slashes were so harsh that industry associations have staged a rare faceoff with authorities, with many worrying that the Hunan drug tender, being the first in the year, may herald a new round of drug price cuts in China.

BioPharmaceutical China

Sanofi Looks To BEYOND To Win China Diabetes Battle

As Sanofi enters a new phase in the insulin race amid heating competition in the country with the highest number of diabetics, it has outlined a new strategy in China, starting from a better understanding of the disease. It is also shifting from simply offering products to providing broader solutions, the firm’s global diabetes head Pierre Chancel says in an interview.

BioPharmaceutical China

Emerging Markets Earnings Roundup: Bayer, Novo Nordisk, Teva (Part 7)

Newer drugs at Bayer helped the bottom line in the third quarter while the world’s top insulin maker Novo Nordisk missed expectations, but held out emerging markets as a bright spot. Teva tussled with analysts on the surprise exit of Jeremy Levin and said that many of the plans during his brief tenure were driven by the board and remain in place.

BioPharmaceutical China
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • Asia
      • Southeast Asia
        • Philippines
  • Parent & Subsidiaries
  • United Laboratories Inc.
  • Senior Management
  • Delfin B Samson, Jr., Pres.
    Leonardo R Abadilla, VP
    Dr. Conrado Dayrit, Dir., R&D
  • Contact Info
  • United Laboratories Inc.
    Phone: (63) 26318501
    65 United St.
    Mandaluyong City, 1550
    Philippines
UsernamePublicRestriction

Register